Microcap Ledger Standard Biotools Inc. $LAB
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Boston, MA
- Fiscal year end
- December 31
- Shares outstanding
- 392,578,808 [10-Q 2026-08-05]
What the company doesAI summary of filing
Standard BioTools develops and sells instrumentation, consumables, and services for life sciences research, primarily in proteomics and genomics. The company serves academic research institutions, translational research centers, cancer centers, and biopharmaceutical companies through a direct sales force in North America, Europe, and Asia-Pacific, as well as through distributors. Standard BioTools generates revenue from research-use-only instruments and consumables; in January 2026, it sold its aptamer-based proteomics business (SomaScan) to Illumina and retained its mass cytometry and microfluidics businesses. The company manufactures products at facilities in Singapore and Canada. [10-K 2026-03-16]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $41.25M | $100.31M | −$56.91M | $270.03M | [10-Q 2026-08-05] |
| FY ended Dec 2025 | $85.33M | −$74.90M | −$74.34M | $120.86M | [10-K 2026-03-16] |
| FY ended Dec 2024 | $91.01M | −$138.88M | −$143.45M | $166.73M | [10-K 2026-03-16] |
- Quarterly cash burn
- −$28.45M
- Cash runway Estimate
- ~28.5 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-08-02 | 371,154,471 | [10-Q 2024-08-06] |
| 2024-11-01 | 372,258,798 | [10-Q 2024-11-06] |
| 2025-03-02 | 378,986,362 | [10-K 2025-03-11] |
| 2025-05-01 | 379,822,268 | [10-Q 2025-05-06] |
| 2025-08-15 | 381,995,102 | [10-Q 2025-08-15] |
| 2025-11-02 | 384,565,414 | [10-Q 2025-11-04] |
| 2026-03-12 | 390,071,506 | [10-K 2026-03-16] |
| 2026-08-03 | 392,578,808 | [10-Q 2026-08-05] |
- Shelf registration
- S-3 filed 2024-06-20; declared effective 2024-06-27 [S-3 2024-06-20]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-07-24. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-07-24 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-07-24] |
| 2026-04-24 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-04-24] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-20 | Mackay Sean | other | 25,729 | $0.67 | [4 2026-08-24] |
| 2026-08-20 | Kim Hanjoon Alex | other | 28,195 | $0.67 | [4 2026-08-24] |
| 2026-08-20 | Egholm Michael | other | 97,627 | $0.67 | [4 2026-08-24] |
| 2026-08-03 | Egholm Michael | other | 362,625 | $0.87 | [4 2026-08-04] |
| 2026-07-23 | Kim Hanjoon Alex | other | 202,476 | $0.90 | [4 2026-07-27] |
| 2026-06-20 | Mackay Sean | grant | 500,000 | — | [4 2026-06-23] |
| 2026-06-18 | Carey Thomas D. | grant | 99,116 | — | [4 2026-06-23] |
| 2026-06-18 | Witney Frank | grant | 99,116 | — | [4 2026-06-23] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-05 | 8-K | Regulation FD disclosure |
| 2026-09-30 | 8-K | Material agreement entered; Material agreement terminated; Regulation FD disclosure |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-05 | 10-Q | Quarterly report |
| 2026-08-05 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-07-30 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-28 | 8-K | Material agreement entered; Regulation FD disclosure |
| 2026-07-24 | 8-K | Listing notice or transfer |
| 2026-06-18 | 8-K | Director or officer change; Shareholder vote results |
| 2026-06-12 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-06-09 | 13D/A | Beneficial ownership report (5%+ holder) |
Alerts for $LAB
Email me when Standard Biotools Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.